News- Noted Scientist in Autoimmune Diseases Joins Advanced Biotherapy's Scientific Board
WOODLAND HILLS, Calif., Mar 3, 2005 (BUSINESS WIRE) -- Advanced Biotherapy,
Inc. (OTCBB: ADVB), dedicated to pioneering the development and use of
therapeutic antibodies, announced today that Dr. Yehuda Shoenfeld, one of the
world's foremost immunologists and Director of the Center for Autoimmune
Diseases at the Sheba Medical Center, Israel's largest hospital, has joined the
Company's scientific advisory board.
Edmond Buccellato, CEO of Advanced Biotherapy, commented: "We are honored to
have Dr. Shoenfeld join our board and look forward to his contribution and depth
of knowledge regarding the emergence of our therapeutic strategy in treating
autoimmune diseases." As the Incumbent of the Laura Schwarz-Kipp Chair for
Research of Autoimmune Diseases in Tel-Aviv University, his clinical and
scientific works have focused on autoimmune/rheumatic diseases, and he has
published more than 1000 papers in peer-reviewed journals such as New England
Journal of Medicine and Lancet, among other notable scientific journals, and has
authored and edited 10 books, some of which are cornerstones in science and
clinical practice, such as "The Mosaic of Autoimmunity," "Infections and
Autoimmunity" and the textbook "Autoantibodies." He is on the editorial board of
32 journals in the field of rheumatology and autoimmunity, and is founding
editor of both the Israel Medical Association Journal, the representative
journal of science and medicine in the English language in Israel, and
Autoimmunity Reviews. Recently Dr. Shoenfeld received the distinguished Carol
Nachman Award for Rheumatology 2004 for outstanding innovative research work in
the field of clinical and experimental rheumatology. We look forward to our
collaboration with him.
About Advanced Biotherapy
The Company has demonstrated the effectiveness of its pioneering scientific
strategy in the use of therapeutic antibodies by conducting investigational
clinical trials treating patients suffering from AIDS, multiple sclerosis,
rheumatoid arthritis, corneal transplant rejection, uveitis and certain
autoimmune skin conditions, including psoriasis and alopecia, all Th-1 mediated
autoimmune diseases which appear to have the same proinflammatory Th-1 activity.
Advanced Biotherapy is headquartered in Los Angeles, with laboratories in
Columbia, Md. The company has an extensive patent portfolio, including 6 issued
patents and over 38 patents pending.
Statements made in this news release, other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties that
could cause actual results to differ materially from the anticipated results or
other expectations expressed in our forward-looking statements. Some of these
forward-looking statements may be identified by the use of words in the
statements such as "hope," "appears," "may," "goal," "anticipate," "estimate,"
"expect," "project," "intend," "planning or plans," "believe," "could," or other
words and terms of similar meaning. The risks and uncertainties which may affect
the development, operations and results of our business include, but are not
limited to, the following: risks associated with clinical trials, the
uncertainties of research and product development programs, the uncertainties of
the regulatory approval process, the risks of competitive products, the risks of
our current capital resources, the uncertainties as to the availability of
future capital and our future capital requirements, and the risks associated
with the extent and breadth of the Company's patent portfolio. There are no
assurances that the Company's product candidates will receive regulatory
approval. The foregoing discussion of the pending clinical investigations and
the effect of the patents issued and pending involves risks and uncertainties,
including, but not limited to, the risks that third parties may be successful in
challenging such patents, or that granted claims may be held invalid or
interpreted differently by a court of law, or that new technologies will be
developed that are superior in treating the diseases targeted by Advanced
Biotherapy, Inc. Readers are cautioned not to place reliance on these
forward-looking statements, which speak only as of the date the statements were
made. See the Company's public filings with the Securities and Exchange
Commission for further information about risks and uncertainties that may affect
the Company and the results or expectations expressed in our forward-looking
statements, including the section captioned "Factors That May Affect The
Company" contained in the Company's Annual Report on Form 10-KSB for the fiscal
year ended December 31, 2003.
SOURCE: Advanced Biotherapy, Inc.
CONTACT: Advanced Biotherapy, Inc.
Edmond Buccellato, 818-883-6716
Fax: 818-883-3353
Email: ed@advancedbiotherapy.com
Website: www.advancedbiotherapy.com
Copyright (C) 2005 Business Wire. All rights reserved. |
